STOCK TITAN
  1. Home
  2. News
  3. ATRC

Atricure Inc - ATRC STOCK NEWS

Welcome to our dedicated news page for Atricure (Ticker: ATRC), a resource for investors and traders seeking the latest updates and insights on Atricure.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Atricure's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Atricure's position in the market.

News
AtriCure Announces Launch of the cryoSPHERE®+ Probe for Post-Operative Pain Management
Rhea-AI Summary
AtriCure, Inc. (Nasdaq: ATRC) has announced the launch of the cryoSPHERE+ cryoablation probe, aimed at post-operative pain management. The new device reduces freeze times by 25% compared to the previous model, enhancing patient care and procedural efficiency. With FDA clearance for pain management in adult and adolescent patients, the cryoSPHERE+ leverages innovative technology to improve outcomes and streamline procedures. The product is currently in a launch phase in the US, with a full rollout expected by the end of the second quarter.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
AtriCure to Announce First Quarter 2024 Financial Results
Rhea-AI Summary
AtriCure, Inc. (ATRC) will release its first quarter 2024 financial results on May 1, 2024. The company specializes in surgical treatments for atrial fibrillation, left atrial appendage management, and post-operative pain management. An audio webcast will be held to discuss the results.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.19%
Tags
earnings
-
News
AtriCure to Participate in the 23rd Annual Needham Virtual Healthcare Conference
Rhea-AI Summary
AtriCure, Inc. (ATRC) will be participating in the 23rd Annual Needham Virtual Healthcare Conference with a fireside chat on April 9, 2024, at 1:30 p.m. EST. The company is known for its innovative surgical treatments for atrial fibrillation, left atrial appendage management, and post-operative pain management. Interested parties can access the live webcast on the company's investor section website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.12%
Tags
conferences
News
AtriCure Reports Fourth Quarter 2023 and Full Year 2023 Financial Results
Rhea-AI Summary
AtriCure, Inc. (Nasdaq: ATRC) reported strong financial results for the fourth quarter and full year 2023, with worldwide revenue reaching $106.5 million in Q4 and $399.2 million for the full year. The company saw a 21.0% year-over-year increase in Q4 revenue and a 20.8% increase for the full year. Despite a net loss of $30.4 million for 2023, AtriCure achieved positive adjusted EBITDA of $19.4 million. The company treated over one million patients to date, showing significant growth and market penetration. AtriCure projects revenue growth of 15% to 17% for 2024, with adjusted EBITDA expected to increase by 34% to 49% over 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.36%
Tags
earnings
-
News
AtriCure to Announce Fourth Quarter and Full Year 2023 Financial Results and Participate in 2024 BTIG Medical Technology Conference
Rhea-AI Summary
AtriCure, Inc. (Nasdaq: ATRC) announced the release of its fourth quarter and full year 2023 financial results on February 15, 2024. The company will host an audio webcast to discuss the results and will also participate in investor meetings at the 2024 BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference on February 13, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.24%
Tags
earnings
-
News
AtriCure Reports Preliminary Results for Fourth Quarter and Full Year 2023, Provides Financial Outlook for 2024
Rhea-AI Summary
AtriCure, a leading innovator in surgical treatments for atrial fibrillation, announced preliminary financial results for Q4 2023 and full year 2023. The company expects a 21% growth in revenue for Q4 2023, with U.S. revenue at $88.7 million and international revenue at $17.8 million. Full year 2023 revenue is expected to be $399.2 million, reflecting a 21% growth over 2022. The company also provided 2024 financial guidance, projecting revenue of $459 million to $466 million, and positive adjusted EBITDA of $26 million to $29 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.06%
Tags
earnings
News
AtriCure Appoints Shlomi Nachman to the Board of Directors
Rhea-AI Summary
AtriCure, a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, has appointed Shlomi Nachman, a highly experienced professional in the medical device industry, to its Board of Directors. Mr. Nachman's extensive experience and leadership roles in the medical device industry, particularly in the Afib treatment market, make him a valuable addition to AtriCure's board. His appointment is expected to contribute to the company's accelerating growth and profitability.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.43%
Tags
management
-
News
AtriCure to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
AtriCure, Inc. (Nasdaq: ATRC) to participate in 42nd Annual J.P. Morgan Healthcare Conference, presenting on January 10, 2024, at 7:30 a.m. Pacific Standard Time. Interested parties can access a live audio webcast on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.88%
Tags
conferences
-
News
AtriCure to Participate in the Piper Sandler 35th Annual Healthcare Conference
Rhea-AI Summary
AtriCure, Inc. (Nasdaq: ATRC) to participate in Piper Sandler 35th Annual Healthcare Conference. Management to have fireside chat on November 29, 2023, at 9:30 a.m. EST. Live webcast available on company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.7%
Tags
conferences
News
AtriCure Releases 2023 ESG Report
Rhea-AI Summary
AtriCure, Inc. (Nasdaq: ATRC) Announces Publication of 2023 ESG Report, Highlighting Corporate Responsibility and Sustainability Initiatives. The report details key accomplishments, including recognition for Diversity, Equity & Inclusion, launching clinical trials, cultivating talent, enhancing employee learning, strengthening relationships across the supply chain, and expanding education to new audiences.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.11%
Tags
none
Stock ATRC logo
Atricure Inc

Nasdaq:ATRC

ATRC Rankings

#2336 Ranked by Market Cap
#3380 Ranked by Stock Gains
N/A Ranked by Dividends

ATRC Stock Data

1.12B
46.01M
3.08%
100.8%
6.71%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
United States
Mason

About ATRC

atricure, inc. provides innovative technologies for the treatment of afib and related conditions. afib affects more than 33 million people worldwide. electrophysiologists and cardiothoracic surgeons around the globe use atricure technologies for the treatment of afib and reduction of afib related complications. atricure’s isolator® synergy™ ablation system is the first and only medical device to receive fda approval for the treatment of persistent afib. atricure’s atriclip left atrial appendage exclusion system products are the most widely sold laa management devices worldwide, with more than 100,000 implanted to date. for more information, visit atricure.com or follow us on twitter @atricure.